long intergenic non-protein coding RNA 1450Genealiases: []
Q-omics provides the consensus-scored LINC01450 profile across patient tissues and cancer cell-line models. LINC01450 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01450 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, LINC01450 RNA expression shows 12,672 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, HNSC, and PDAC as cancer lineages where LINC01450 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01450 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01450 survival associations across molecular data types. LINC01450 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01450 RNA expression–survival associations across cancer types. High LINC01450 expression shows unfavorable associations in BLCA, LUAD, MESO, UCEC, LGG and THCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01450 RNA expression.
This table summarizes LINC01450 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01450. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01450 shows higher tumor expression in HNSC, LUSC and KIRP. The HNSC box plot shows higher LINC01450 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p < 0.001).
This table shows molecular features associated with LINC01450 in patient tissues and cancer cell lines. In patient samples, LINC01450 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
